

# Medicines Optimisation intervention brief

## Medicines Optimisation Incentive Scheme 2018/19 Cost Saving Intervention

<b>TITLE?</b>
2.1.5b Prescribe oxycodone prolonged-release as either Longtec or Abtard brand
<b>WHAT?</b>
<ul style="list-style-type: none"> <li>The Drug Tariff price for generic oxycodone prolonged-release is based on the OxyContin brand.</li> <li>Branded generics have become available at a lower acquisition cost.</li> <li>Longtec brand provides the whole range of strengths. It is now well established in the market and is available at a much lower acquisition cost than the generic.</li> <li>Abtard is a newer product to the market and is available in all strengths except 120mg.</li> </ul>
<b>WHY?</b>
<ul style="list-style-type: none"> <li>On current usage there are possible savings of up to £130,000 per annum by using Longtec or Abtard.</li> <li>Abtard is currently has the same list price as Longtec.</li> </ul>
<b>WHO?</b>
<ul style="list-style-type: none"> <li>All patients with a repeat prescription for oxycodone prolonged-release tablets or OxyContin tablets.</li> </ul>
<b>TIPS?</b>
<ul style="list-style-type: none"> <li>Longtec is the specified brand of oxycodone in the local Chronic Pain Guidelines so there may be less confusion if this product is chosen.</li> </ul>
<b>HOW?</b>
<ul style="list-style-type: none"> <li>Search for all patients taking oxycodone prolonged-release 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg and 120mg tablets or OxyContin 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg and 120mg tablets.</li> <li>Switch to the equivalent strength of Longtec or Abtard.</li> </ul>
<b>SO WHAT?</b>
<ul style="list-style-type: none"> <li>Realise savings.</li> </ul>
<b>FURTHER INFORMATION</b>
<ul style="list-style-type: none"> <li>Morphine is the preferred first line opioid. Oxycodone should be reserved for patients who cannot tolerate morphine.</li> <li>OxyContin and Longtec are identical products but for commercial reasons have a different pricing structure.            Ref: <a href="http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con316204.pdf">http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con316204.pdf</a></li> <li>There is an additional rebate scheme available for Abtard.</li> <li>Abtard has been assessed by PrescQIPP as having equal efficacy to OxyContin.</li> </ul>

